Abstract 355: The Economic and Clinical Burden of High Risk Symptomatic Peripheral Artery Disease
Background: A better understanding of high risk groups of patients with symptomatic peripheral artery disease (SPAD) may improve targeting care and reducing costs.
Methods: Patient records from Jan 1, 2006 through June 30, 2010 were extracted from the MarketScan Commercial and Encounters database (MCED) using a SPAD selection algorithm. The earliest date of a record of SPAD was the index date and a period of 1 year pre- and 3 years post-index was the study time frame. Patients with stroke/TIA, with bleeding complications and contraindications to anti-platelet therapy were excluded. Descriptive and univariate statistics comparing pre- and post-index CV and PAD related events, resource utilization and costs among the diabetic vs. non-diabetic SPAD, recent MI vs. non-recent MI SPAD, and diabetes and recent MI vs non-diabetes and recent MI SPAD patients were generated.
Results: Out of a total of 16,663 SPAD patients, 36.0% had comorbid diabetes (N= 6,002), 5.8% had a recent MI (N=965) and 2.6% (N=425) had diabetes and a recent MI. Patient demographics appear to be similar but comorbid conditions and the Charlson Comorbidity Index (CCI) are significantly higher among high risk groups when compared to non-high risk counterparts (p<0.0001). CV related outcomes; PAD-related and CV-related procedures; other medical resource use and costs (both all-cause and PAD-related) are significantly higher among high risk SPAD patients (see Table 1).
Conclusions: Effective secondary prevention therapies may reduce morbidity and costs associated with these high risk groups.
Author Disclosures: M. Chase: A. Employment; Significant; Merck & Co. H. Friedmann: B. Research Grant; Significant; Merck & Company, Novartis, Gilead, Bristol Myers Squibb. G. Consultant/Advisory Board; Significant; Merck & Co., Novartis. P. Navaratnam: B. Research Grant; Significant; Merck & Co., Novartis, Gilead, Bristol Myers Squibb. G. Consultant/Advisory Board; Significant; Merck & Co., Novartis. K. Heithoff: A. Employment; Significant; Merck & Co. R.J. Simpson: G. Consultant/Advisory Board; Modest; Merck & Co., Pfizer, Amgen.
- © 2015 by American Heart Association, Inc.